Mortality in the TRITON trial: update from the FDA prasugrel action package.
Serebruany
Victor L
VL
D017277:Drug Approval; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy / Q000401:mortality*; D010879:Piperazines / Q000627:therapeutic use*; D000068799:Prasugrel Hydrochloride; D058919:Purinergic P2 Receptor Antagonists; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D013876:Thiophenes / Q000627:therapeutic use*; D015912:Thrombolytic Therapy / Q000379:methods*; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration
D010879:Piperazines; D058919:Purinergic P2 Receptor Antagonists; D013876:Thiophenes; D000068799:Prasugrel Hydrochloride